These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8783295)

  • 1. Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen.
    Riemens SC; Oostdijk A; van Doormaal JJ; Thijn CJ; Drent G; Piers DA; Groen EW; Meerman L; Slooff MJ; Haagsma EB
    Osteoporos Int; 1996; 6(3):213-8. PubMed ID: 8783295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study.
    Shane E; Rodino MA; McMahon DJ; Addesso V; Staron RB; Seibel MJ; Mancini D; Michler RE; Lo SH
    J Heart Lung Transplant; 1998 Nov; 17(11):1089-96. PubMed ID: 9855448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Diamond T; Campbell J; Bryant C; Lynch W
    Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone metabolism in orthotopic liver transplantation: a prospective study.
    Floreani A; Fries W; Luisetto G; Burra P; Fagiuoli S; Boccagni P; Della Rovere GR; Plebani M; Piccoli A; Naccarato R
    Liver Transpl Surg; 1998 Jul; 4(4):311-9. PubMed ID: 9649646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.
    Zamberlan N; Castello R; Gatti D; Rossini M; Braga V; Fracassi E; Adami S
    Osteoporos Int; 1997; 7(2):133-7. PubMed ID: 9166393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation.
    Monegal A; Navasa M; Guañabens N; Peris P; Pons F; Martinez de Osaba MJ; Rimola A; Rodés J; Muñoz-Gómez J
    Calcif Tissue Int; 1997 Feb; 60(2):148-54. PubMed ID: 9056162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral density in the long term after liver transplantation.
    Hamburg SM; Piers DA; van den Berg AP; Slooff MJ; Haagsma EB
    Osteoporos Int; 2000; 11(7):600-6. PubMed ID: 11069194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation.
    Feller RB; McDonald JA; Sherbon KJ; McCaughan GW
    Liver Transpl Surg; 1999 Sep; 5(5):407-13. PubMed ID: 10477842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.
    Anderson FH; Francis RM; Bishop JC; Rawlings DJ
    Age Ageing; 1997 Sep; 26(5):359-65. PubMed ID: 9351480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
    J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
    Harris ST; Watts NB; Jackson RD; Genant HK; Wasnich RD; Ross P; Miller PD; Licata AA; Chesnut CH
    Am J Med; 1993 Dec; 95(6):557-67. PubMed ID: 8259772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis.
    Shiota E; Tsuchiya K; Yamaoka K; Kawano O
    J Orthop Sci; 2001; 6(2):133-6. PubMed ID: 11484098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis.
    Orimo H; Shiraki M; Hayashi Y; Hoshino T; Onaya T; Miyazaki S; Kurosawa H; Nakamura T; Ogawa N
    Calcif Tissue Int; 1994 May; 54(5):370-6. PubMed ID: 8062152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
    Sato S; Ohosone Y; Suwa A; Yasuoka H; Nojima T; Fujii T; Kuwana M; Nakamura K; Mimori T; Hirakata M
    J Rheumatol; 2003 Dec; 30(12):2673-9. PubMed ID: 14719212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation.
    Atamaz F; Hepguler S; Akyildiz M; Karasu Z; Kilic M
    Osteoporos Int; 2006; 17(6):942-9. PubMed ID: 16550299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
    Fogelman I; Herd RJ; Blake GM; Balena R
    Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3.
    Gorai I; Chaki O; Taguchi Y; Nakayama M; Osada H; Suzuki N; Katagiri N; Misu Y; Minaguchi H
    Calcif Tissue Int; 1999 Jul; 65(1):16-22. PubMed ID: 10369728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.